Gansu Fuzheng Pharmaceutical Wins Drug Patent Battle
This article was originally published in PharmAsia News
Executive Summary
Gansu Fuzheng Pharmaceutical Technologies and Gansu Xinlanyao Pharmaceutical, which jointly produce Zhenqi Fuzheng Capsule, received a Lunar New Year gift from China's State FDA: the announcement that it has terminated Guizhou Xinbang Pharmaceutical's Zhenqi Fuzheng Capsule production effective from Dec. 31. The two Gansu firms have been offering the capsule since 1993 and secured China's intellectual property rights in 2003. However, Guizhou Xinbang managed to get national approval to produce its "concentrated" version of the drug in Guizhou and Sichuan in 2001. The Gansu partners fought for seven years to regain the protected status of the patented drug, a quest supported by Gansu province's government and drug administration. (Click here for more - Chinese Language)